EvokAI Creative Labs Sets Date for Share Consolidation
EvokAI Creative Labs has announced the completion of its previously disclosed 10:1 share consolidation, effective February 05, 2025. Following the consolidation, the company will have approximately 7,605,493 common shares outstanding.
The consolidation will be implemented under new CUSIP (30053J200) and ISIN (CA30053J2002) numbers. Shareholders holding uncertificated shares will have their accounts automatically adjusted by Endeavor Trust or their respective brokers. Registered shareholders with physical certificates will receive instructions for surrendering their current certificates for post-consolidation replacements.
The company expects this consolidation to potentially increase financial community interest, broaden its investor base, improve trading liquidity, and reduce shareholder transaction costs.
EvokAI Creative Labs ha annunciato il completamento della sua precedentemente divulgata consolidazione azionaria in un rapporto di 10:1, effettiva dal 5 febbraio 2025. Dopo la consolidazione, la società avrà circa 7.605.493 azioni ordinarie in circolazione.
La consolidazione sarà attuata sotto nuovi numeri CUSIP (30053J200) e ISIN (CA30053J2002). Gli azionisti che detengono azioni non certificate vedranno i loro conti automaticamente regolati da Endeavor Trust o dai rispettivi broker. Gli azionisti registrati con certificati fisici riceveranno istruzioni per la restituzione dei loro attuali certificati in cambio di sostituti post-consolidazione.
L'azienda si aspetta che questa consolidazione possa aumentare l'interesse della comunità finanziaria, ampliare la sua base di investitori, migliorare la liquidità degli scambi e ridurre i costi delle transazioni per gli azionisti.
EvokAI Creative Labs ha anunciado la finalización de su consolidación de acciones de 10:1 previamente divulgada, efectiva a partir del 5 de febrero de 2025. Después de la consolidación, la compañía tendrá aproximadamente 7,605,493 acciones ordinarias en circulación.
La consolidación se implementará bajo nuevos números CUSIP (30053J200) y ISIN (CA30053J2002). Los accionistas que posean acciones no certificadas verán sus cuentas ajustadas automáticamente por Endeavor Trust o sus respectivos corredores. Los accionistas registrados con certificados físicos recibirán instrucciones para entregar sus certificados actuales a cambio de reemplazos post-consolidación.
La empresa espera que esta consolidación pueda aumentar el interés de la comunidad financiera, ampliar su base de inversores, mejorar la liquidez en el comercio y reducir los costos de transacción para los accionistas.
EvokAI Creative Labs는 2025년 2월 5일부터 적용되는 10:1 주식 통합의 완료를 발표했습니다. 통합 후 회사는 약 7,605,493 주식이 발행됩니다.
통합은 새로운 CUSIP (30053J200) 및 ISIN (CA30053J2002) 번호로 시행됩니다. 인증되지 않은 주식을 보유한 주주들은 Endeavor Trust 또는 각자의 중개인을 통해 자동으로 계좌가 조정됩니다. 물리적 증서를 보유한 등록된 주주들은 통합 후 교환할 현재 증서를 제출하는 안내를 받을 것입니다.
회사는 이번 통합이 금융 커뮤니티의 관심을 증가시키고 투자자 기반을 확대하며 거래 유동성을 개선하고 주주 거래 비용을 절감할 것으로 예상하고 있습니다.
EvokAI Creative Labs a annoncé l'achèvement de sa consolidation d'actions dans un rapport de 10:1, effective à partir du 5 février 2025. Suite à la consolidation, la société aura environ 7 605 493 actions ordinaires en circulation.
La consolidation sera mise en œuvre sous de nouveaux numéros CUSIP (30053J200) et ISIN (CA30053J2002). Les actionnaires détenant des actions non certifiées verront leurs comptes automatiquement ajustés par Endeavor Trust ou leurs courtiers respectifs. Les actionnaires enregistrés possédant des certificats physiques recevront des instructions pour remettre leurs certificats actuels en échange de remplacements après la consolidation.
L'entreprise s'attend à ce que cette consolidation puisse potentiellement accroître l'intérêt de la communauté financière, élargir sa base d'investisseurs, améliorer la liquidité des échanges et réduire les coûts de transaction pour les actionnaires.
EvokAI Creative Labs hat den Abschluss ihrer zuvor bekannt gegebenen 10:1 Aktienkonsolidierung angekündigt, die ab dem 5. Februar 2025 wirksam wird. Nach der Konsolidierung wird das Unternehmen voraussichtlich etwa 7.605.493 Stammaktien outstanding haben.
Die Konsolidierung wird unter neuen CUSIP (30053J200) und ISIN (CA30053J2002) Nummern umgesetzt. Aktionäre, die nicht zertifizierte Aktien halten, sehen, dass ihre Konten automatisch von Endeavor Trust oder deren jeweiligen Brokern angepasst werden. Registrierte Aktionäre mit physischen Zertifikaten erhalten Anweisungen zur Rückgabe ihrer aktuellen Zertifikate gegen Ersatz nach der Konsolidierung.
Das Unternehmen erwartet, dass diese Konsolidierung das Interesse der Finanzgemeinschaft potenziell steigern, die Investorenbasis erweitern, die Handelsliquidität verbessern und die Transaktionskosten für die Aktionäre senken kann.
- Share consolidation may improve trading liquidity
- Potential for broader investor base and increased institutional interest
- Reduction in shareholder trading costs
- Significant reduction in outstanding shares could impact trading volume
VANCOUVER, BC / ACCESS Newswire / February 3, 2025 / EvokAI Creative Labs Inc. (TSXV:OKAI)(OTCQB:OKAIF) ("EvokAI" or the "Company"), a leading MedTech AI-powered company dedicated to the development of transformational and innovative technologies for the healthcare sector, further to its press release on December 17, 2024, announces that it will complete the previously announced consolidation of its issued and outstanding common shares on a 10:1 basis (the "Consolidation"), effective at the opening of the market on Wednesday, February 05, 2025. Subject to the Consolidation, the Company will have approximately 7,605,493 common shares issued and outstanding.
New share certificates will be issued under new CUSIP and ISIN numbers, which are CUSIP: 30053J200 / ISIN: CA30053J2002. Holders of shares of the Company who hold uncertificated shares (that is shares held in book-entry form and not represented by a physical share certificate), either as registered holders or beneficial owners, will have their existing book-entry account(s) electronically adjusted by Endeavor Trust Corporation ("Endeavor"), the Company's transfer agent or, in the case of beneficial shareholders, by their brokerage firms, banks, trusts or other nominees that hold in street name for their benefit. Such holders generally do not need to take any additional actions to exchange their pre-consolidation shares for post-consolidation shares. If you hold your shares with such a bank, broker or other nominee, and if you have questions in this regard, you are encouraged to contact your nominee.
Registered shareholders holding share certificates will be mailed a letter of transmittal from Endeavor advising of the Consolidation and instructing them to surrender the share certificates representing pre-consolidation shares for replacement certificates or a direct registration advice representing their post-consolidation shares.
The Company believes that the Consolidation may have the effect of, among other things: increasing the interest of the financial community in the Company and potentially broadening its pool of investors; improving trading liquidity; and reducing trading commissions and other transaction costs for shareholders.
About EvokAI Creative Labs Inc.
EvokAI is a MedTech AI-powered company dedicated to the development of transformational and innovative technologies for the modern healthcare sector. We deploy machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions and provide more accurate diagnoses. EvokAI tailors its AI algorithms across the whole healthcare system, from hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations, to medical professionals, patients, healthy individuals aiming at preventing any kind of disease and beyond, protecting the aging genome.
On behalf of the Board of Directors of EvokAI Creative Labs Inc.
Alejandro Antalich
CEO & Director
For more information, please contact:
EvokAI Creative Labs Inc.
Alejandro Antalich
Chief Executive Officer
Email: hello@evokailabs.com
Phone: +358 50 5512 848
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Generally, any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information or statements.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets; the Company's limited operating history; future capital needs and uncertainty of additional financing; the competitive nature of the technology industry; unproven markets for the Company's product offerings; lack of regulation and customer protection; the need for the Company to manage its planned growth and expansion; the effects of product development and need for continued technology change; protection of proprietary rights; network security risks; the ability of the Company to maintain properly working systems; foreign currency trading risks; use and storage of personal information and compliance with privacy laws; use of the Company's services for improper or illegal purposes; global economic and financial market conditions; uninsurable risks; changes in project parameters as plans continue to be evaluated; and those factors described under the heading "Risks Factors" in the Company's filing statement dated March 27, 2023 available on SEDAR+. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements and information. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward-looking information, will prove to be accurate. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.
SOURCE: EvokAI Creative Labs Inc.
View the original press release on ACCESS Newswire
FAQ
What is the share consolidation ratio for EvokAI (OKAIF) announced on February 3, 2025?
How many shares will EvokAI (OKAIF) have outstanding after the February 2025 consolidation?
What are the new CUSIP and ISIN numbers for EvokAI (OKAIF) following the 2025 consolidation?
What benefits does EvokAI expect from the 2025 share consolidation?
What actions do EvokAI (OKAIF) shareholders need to take for the 2025 consolidation?
